Jilin Zhengye is a China-based veterinary vaccine manufacturer with over 20 years in the business, operating through its subsidiary Jilin Zhengye Biotechnology in Jilin Province. The company develops, manufactures, and sells vaccines for livestock — primarily swine and poultry, but also cattle, sheep, and goats — protecting animals from infectious diseases like swine fever, porcine epidemic diarrhea, Newcastle disease, and avian influenza. Jilin Zhengye holds 50 approved veterinary vaccines and sells primarily in China, which accounts for roughly 97% of revenue, with a small export presence in Vietnam, Pakistan, and Egypt. The company sells through distributors covering all 29 provincial-level regions in China, directly to large breeding operations, and through government procurement tenders for compulsory vaccination programs. Revenue is driven by vaccine dose volumes, product mix (with higher-value combination vaccines commanding better pricing than commodity single-antigen vaccines), and channel mix. The cost structure includes raw materials, manufacturing labor, and royalties paid to research institutes for licensed technologies. Jilin Zhengye is expanding its portfolio through new combination vaccines, pursuing entry into the companion animal market with feline and canine vaccines still in the regulatory pipeline, and targeting new export markets in Africa and Central Asia. The company has also flagged M&A interest in the pet animal health space and established a Beijing joint venture to strengthen sales and research institution relationships.